Arix Bioscience has announced various management and board changes, and the appointment of Joe Anderson as the company’s new CEO.
Jonathan Peacock, executive chairman, will become non-executive chairman and Sir Christopher Evans will retire from the board, remaining a consultant to the company. These changes will take place with immediate effect, recognising the continued strong performance of the portfolio and pipeline development.
Jonathan Peacock, Chairman of Arix Bioscience, commented on the changes: “Arix has rapidly built a strong, diverse portfolio and a top tier investment team who continue to build value, both in our portfolio companies and for our shareholders. We have benefited from Joe’s focus as CIO over the recent months and the changes announced today build on this and reflect a clear shift towards a leaner organisation that will continue to drive the Company’s strong growth.”